Valeo Pharma
  • About Us
    • Overview
    • Board of Directors
    • Executive Team
  • Product Portfolio
    • Respiratory / Allergy
    • Ophthalmology
    • Specialty Products
    • Neurology
    • Oncology
  • Partnering
  • Investors
    • Investor Relations
    • Stock information
    • Corporate Presentation
    • Financial Reports
    • Newsroom
    • Webcasts / Events
    • SEDAR documents
  • Careers
  • Contact
  • Français
Select Page
VALEO PHARMA REPORTS RECORD QUARTERLY REVENUES FOR THE FIRST QUARTER 2023

VALEO PHARMA REPORTS RECORD QUARTERLY REVENUES FOR THE FIRST QUARTER 2023

by Fred Dumais | Mar 15, 2023 | News Release

• Fifth consecutive quarter of revenue growth at $13.2 million in Q1-23, up 210% over Q1-22 • Fifth consecutive quarter of adjusted gross profit increase at $4.2 million, up 178% over Q1-22 • Fifth consecutive quarter of adjusted EBITDA loss reduction at $2.2 million,...
VALEO PHARMA TO HOST FIRST QUARTER 2023 RESULTS CONFERENCE CALL / WEBCAST     

VALEO PHARMA TO HOST FIRST QUARTER 2023 RESULTS CONFERENCE CALL / WEBCAST     

by Fred Dumais | Mar 9, 2023 | News Release

MONTREAL, QUEBEC , March 9, 2023 – Valeo Pharma Inc. (TSX:VPH, OTCQB: VPHIF, FSE:VP2) (“Valeo” or the “Company”), a Canadian pharmaceutical company, announced today that it will report its financial results and highlights for the first quarter ended January 31, 2023...
VALEO PHARMA OBTAINS PUBLIC REIMBURSEMENT FOR ONSTRYV® IN QUEBEC

VALEO PHARMA OBTAINS PUBLIC REIMBURSEMENT FOR ONSTRYV® IN QUEBEC

by Fred Dumais | Feb 7, 2023 | News Release

Quebec public reimbursement coverage to facilitate and expand medication access for Parkinson’s patients in Quebec MONTREAL, QUEBEC , February 7, 2023 – Valeo Pharma Inc. (TSX:VPH, OTCQB: VPHIF, FSE: VP2) (“Valeo” or the “Company”), a Canadian pharmaceutical company,...
VALEO PHARMA REPORTS RECORD QUARTERLY REVENUES FOR THE FIRST QUARTER 2023

VALEO PHARMA REPORTS RECORD QUARTERLY AND ANNUAL REVENUES FOR THE FOURTH QUARTER AND THE FISCAL YEAR 2022

by Fred Dumais | Jan 30, 2023 | News Release

Record quarterly revenues of $12.7 million in Q4-22, up 274% over Q4-21 Record revenues in 2022 of $27.7 million, up 105% over 2021 Record revenues forecasted in Q1-23 Creation of Ophthalmology Business Unit following the addition of XIIDRA® and SIMBRINZA®, expansion...
VALEO PHARMA ANNOUNCES FILING OF A NEW DRUG SUBMISSION-COVID 19 WITH HEALTH CANADA FOR SABIZABULIN FOR THE TREATMENT OF HOSPITALIZED COVID-19 PATIENTS

VALEO PHARMA ANNOUNCES FILING OF A NEW DRUG SUBMISSION-COVID 19 WITH HEALTH CANADA FOR SABIZABULIN FOR THE TREATMENT OF HOSPITALIZED COVID-19 PATIENTS

by Fred Dumais | Jan 26, 2023 | News Release

In the final analysis of the Phase 3 cinical study conducted by Veru Inc., sabizabulin showed a 51.6% reduction in deaths compared to placebo in hospitalized adult patients with moderate to severe COVID-19 who are at high risk for ARDS Sabizabulin also showed a...
VALEO PHARMA TO HOST FOURTH QUARTER AND YEAR-END 2022 RESULTS CONFERENCE CALL / WEBCAST     

VALEO PHARMA TO HOST FOURTH QUARTER AND YEAR-END 2022 RESULTS CONFERENCE CALL / WEBCAST     

by Fred Dumais | Jan 25, 2023 | News Release

MONTREAL, QUEBEC , January 25, 2023 – Valeo Pharma Inc. (TSX:VPH, OTCQB: VPHIF, FSE:VP2) (“Valeo” or the “Company”), a Canadian pharmaceutical company, announced today that it will report its financial results and highlights for the fourth quarter and year ended...

Recent News

  • VALEO PHARMA ANNONCE DES REVENUS TRIMESTRIELS RECORDS POUR LE PREMIER TRIMESTRE DE 2023 March 15, 2023
  • VALEO PHARMA REPORTS RECORD QUARTERLY REVENUES FOR THE FIRST QUARTER 2023 March 15, 2023
  • VALEO PHARMA TIENDRA UNE CONFÉRENCE TÉLÉPHONIQUE / WEBDIFFUSION POUR SES RÉSULTATS DU PREMIER TRIMESTRE DE 2023 March 9, 2023
  • VALEO PHARMA TO HOST FIRST QUARTER 2023 RESULTS CONFERENCE CALL / WEBCAST      March 9, 2023

Stay in the loop

I consent to receive news, updates and special offers from Valeo Pharma and it’s affiliates.

Contact us

1-855-694-0151
[email protected]
16667 Hymus Blvd.
Kirkland, QC H9H 4R9

  • About Us
  • Board of Directors
  • Management Team
  • Careers
  • Our Products
  • Business Development
  • Investors Overview
  • Newsroom
  • Stock Information
  • Financial Reports
  • Contact Us
  • Français

© 2022 Valeo Pharma. All rights reserved.

Speak to a professional

I want to speak to:

9 + 12 =